- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Nemtabrutinib, Ibrutinib, Acalabrutinib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 49
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 45 more
Location Directory
Clinical trials in Phoenix, Arizona
This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8144
Shown on this page
12
Current sort
Recently updated
Location scope
Phoenix, AZ
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 181–192 of 8,144 matching trials in Phoenix, AZ.
Live ClinicalTrials.gov results.
Institutions in Phoenix
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Higher-risk Myelodysplastic Syndrome
- Interventions
- Lisaftoclax (APG-2575), Azacitidine Injection, Placebo
- Drug · Other
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more
- Conditions
- Pompe Disease (Late-onset), Pompe Disease Late-Onset, LOPD
- Interventions
- AB-1009 (GAA Gene)
- Genetic
- Lead sponsor
- AskBio Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Irvine, California • Palo Alto, California + 6 more
- Conditions
- Major Depressive Disorder
- Interventions
- Azetukalner
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 58 more
- Conditions
- Secondary Progressive Multiple Sclerosis (SPMS)
- Interventions
- Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
- Interventions
- Somatropin, Placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease
- Interventions
- Treprostinil Palmitil Inhalation Powder, Placebo
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Tremelimumab, Rilvegostomig, Bevacizumab, Atezolizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- WATCHMAN FLX Pro LAAC Device
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,857 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more
- Conditions
- Chronic Spontaneous Urticaria (CSU)
- Interventions
- Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
- Conditions
- COVID-19
- Interventions
- CVXGA (CVXGA50), COMIRNATY®
- Biological
- Lead sponsor
- CyanVac LLC
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 55
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Chula Vista, California + 44 more
- Conditions
- Female Contraception
- Interventions
- Transdermal system containing progestin
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 1,630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 40 more